Aurobindo Pharma on said three of its facilities have been classified post-inspection as Official Action Indicated (OAI) by the USFDA. The classification means the facility concerned requires regulatory and/or administrative actions. The firm is confident that the OAI classification would not impact supplies from these facilities. Aurobindo Pharma shares tanked 7.53% to close the day at ₹670.25 apiece on the BSE.
The announcement by the company saw the stock, which opened at ₹725 apiece, touching an intra-day low of ₹662.15. It closed at ₹670.25, a decline of ₹54.55 per share or 7.53%.
